FDA Approval for Topotecan Hydrochloride

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Brand name(s): Hycamtin®

  • Approved for cervical cancer

Full prescribing information is available, including clinical trial information, safety, dosing, drug-drug interactions and contraindications.

On June 14, 2006, the U.S. Food and Drug Administration approved topotecan hydrochloride (Hycamtin®, made by GlaxoSmithKline) in combination with cisplatin for the treatment of stage IVB recurrent or persistent carcinoma of the cervix (cervical cancer) that is not amenable to curative treatment with surgery and/or radiation therapy.

Topotecan was evaluated in women with stage IVB recurrent or persistent cervical cancer in one open-label, multicenter, cooperative group trial. Two hundred ninety-three patients were randomized to six cycles of topotecan hydrochloride 0.75 mg/m2 IV over 30 minutes for three consecutive days (Days 1-3) plus cisplatin 50 mg/m2 IV over one hour on Day 1 every 21 days or to cisplatin alone at the same dose and schedule.

The primary endpoint was overall survival. The median survival was 9.4 months in the topotecan hydrochloride plus cisplatin group and 6.5 months in the cisplatin group (log-rank p = 0.033). The unadjusted hazard ratio was 0.76 (95 percent CI: 0.59, 0.98).

The most common toxicity on the combination arm was myelosuppression. Grade 3-4 hematologic (of the blood or bone marrow) adverse events occurring more commonly in the combination arm included neutropenia (74 percent vs. 2 percent), anemia (40 percent vs. 22 percent), thrombocytopenia (33 percent vs. 3 percent), and febrile neutropenia (18 percent vs. 8 percent). Grade 3-4 nonhematologic adverse events reported more commonly in the combination treatment arm included pain, nausea and vomiting, metabolic-laboratory, and hepatic.

  • Updated: July 3, 2013